Association between Beta Adrenergic Receptor Polymorphism and Ischemic Stroke: A Meta-Analysis.
Amit Kumar1, Manya Prasad1, Pradeep Kumar1
1Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
Journal of Stroke
|June 11, 2015
Summary
The beta-2 adrenergic receptor (β2AR) Gln27Glu polymorphism is linked to a higher risk of ischemic stroke. This genetic variation may increase susceptibility to this serious vascular condition.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Pharmacogenomics
Background:
- Ischemic stroke is a leading cause of death and disability worldwide.
- Genetic factors play a role in stroke risk.
- The beta-2 adrenergic receptor (β2AR) gene is a potential candidate for stroke risk association.
Purpose of the Study:
- To conduct a meta-analysis to precisely determine the association between beta-2 adrenergic receptor (β2AR) polymorphism and ischemic stroke.
- To evaluate the risk conferred by specific β2AR polymorphisms on ischemic stroke development.
Main Methods:
- Systematic literature search of published case-control studies on β2AR polymorphism and ischemic stroke.
- Meta-analysis using pooled Odds Ratio (OR) and 95% Confidence Intervals (CI) with RevMan software.
- Analysis included allelic and genotypic associations across selected studies.
Main Results:
- Three studies (1,642 cases, 1,673 controls) were included.
- Gln27Glu polymorphism of β2AR was associated with increased ischemic stroke risk under recessive (OR 2.09) and dominant (OR 1.47) models.
- A significantly higher frequency of the Glu27 allele of β2AR was observed in ischemic stroke patients (OR 1.58).
Conclusions:
- The Gln27Glu polymorphism in the β2AR gene is significantly associated with an increased risk of ischemic stroke.
- This finding highlights the potential role of β2AR genetic variations in stroke pathogenesis.
- Further research may explore therapeutic strategies targeting β2AR pathways.
Related Concept Videos
01:26Adrenergic Receptors: β Subtype
4.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.6K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:31Adrenergic Receptors: ɑ Subtype
3.3K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.3K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.9K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K